Clinical Study
Clinical Outcome of Bortezomib Retreatment in Patients with Relapsed or Refractory Multiple Myeloma
Figure 2
Overall survival (OS) according to time interval (months) between initial bortezomib-based therapy and retreatment. Patients who received bortezomib retreatment ≥12 months from the final initial therapy had a 1-year OS rate of 65.8% (95% CI: 43.5–88.1) and patients receiving retreatment after <12-month interval had a 1-year OS rate of 41.7% (95% CI: 13.9–69.5) ().